TALVEY – Talk Bio

Actionable Insights Powered by AI

Johnson & Johnson Highlights Promising Combination of TALVEY and TECVAYLI for Relapsed or Refractory Multiple Myeloma

7 months ago talkbio0Tagged Antibodies, Bispecific, Combined, EMD, Extramedullary Disease in Plasma Cell Myeloma, Frequency of Responses, Refractory Plasma Cell Myeloma, Relapsing course, Response process, Talquetamab, TALVEY, Teclistamab, TECVAYLI

TALVEY (talquetamab), TECVAYLI (teclistamab), Relapsed or Refractory Multiple Myeloma (RRMM), Bispecific Antibody Combination, Extramedullary Disease (EMD), High Response Rates, Durable Responses

FDA Approves Johnson & Johnson’s New Multiple Myeloma Therapy

9 months ago talkbio0Tagged Antibodies, Bispecific, Approved, CAR-T, Carvykti, Cell Therapy, DARALEXASPRO, Johnson & Johnson, Multiple Myeloma, TALVEY, United States Food and Drug Administration

FDA approval, Johnson & Johnson, multiple myeloma, CAR-T cell therapy, bispecific antibody, TALVEY, CARVYKTI, DARALEXASPRO